RICTOR
RICTOR (Rapamycin-insensitive companion of mTOR) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Lung cancer, Breast cancer and 5 more.
Overview
Component of the mechanistic target of rapamycin complex 2 (mTORC2), which transduces signals from growth factors to pathways involved in proliferation, cytoskeletal organisation, lipogenesis and anabolic output. In response to growth factors, mTORC2 phosphorylates and activates AGC protein kinase family members, including AKT (AKT1, AKT2 and AKT3), PKC (PRKCA, PRKCB and PRKCE) and SGK1. In contrast to mTORC1, mTORC2 is nutrient-insensitive.
CIViC holds 4 clinical evidence items and 0 assertions across 1 variant, naming Vistusertib, Sapanisertib, MTOR Kinase Inhibitor AZD8055 and Onatasertib. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.61, genetic association 0.00, somatic mutation 0.98).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RICTOR (Rapamycin-insensitive companion of mTOR) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Lung cancer, Breast cancer and 5 more.
- 1 · What it is
RICTOR (Rapamycin-insensitive companion of mTOR) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Lung cancer, Breast cancer and 5 more.
- 2 · What goes wrong in cancer
Component of the mechanistic target of rapamycin complex 2 (mTORC2), which transduces signals from growth factors to pathways involved in proliferation, cytoskeletal organisation, lipogenesis and anabolic output.
- 3 · How drugs use it
No product in this corpus aims at RICTOR yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:28611 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6R327 (protein name, function text, keywords and locations (REST API)); CIViC gene RICTOR (4 evidence items, 0 assertions, 1 variants; diseases: Lung Small Cell Carcinoma, Lung Adenocarcinoma, Gastric Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000164327 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: colorectal cancer 0.50, gastric cancer 0.51, melanoma 0.54, skin cancer 0.52, breast cancer 0.54, lung cancer 0.57 (GraphQL API, CC0))
Biology
Component of the mechanistic target of rapamycin complex 2 (mTORC2), which transduces signals from growth factors to pathways involved in proliferation, cytoskeletal organisation, lipogenesis and anabolic output. In response to growth factors, mTORC2 phosphorylates and activates AGC protein kinase family members, including AKT (AKT1, AKT2 and AKT3), PKC (PRKCA, PRKCB and PRKCE) and SGK1. In contrast to mTORC1, mTORC2 is nutrient-insensitive. Within the mTORC2 complex, RICTOR probably acts as a molecular adapter. RICTOR is responsible for the FKBP12-rapamycin-insensitivity of mTORC2. mTORC2 plays a critical role in AKT1 activation by mediating phosphorylation of different sites depending on the context, such as 'Thr-450', 'Ser-473', 'Ser-477' or 'Thr-479', facilitating the phosphorylation of the activation loop of AKT1 on 'Thr-308' by PDPK1/PDK1 which is a prerequisite for full activation. mTORC2 catalyses the phosphorylation of SGK1 at 'Ser-422' and of PRKCA on 'Ser-657'. The mTORC2 complex also phosphorylates various proteins involved in insulin signalling, such as FBXW8 and IGF2BP1. mTORC2 acts upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors. mTORC2 promotes the serum-induced formation of stress-fibres or F-actin. Location: Cell membrane; Endoplasmic reticulum membrane; Lysosome membrane (UniProt). Locus 5p13.1 (HGNC).
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.51 with gastric cancer (MONDO_0001056); CIViC evidence names this disease
- Lung cancer: Open Targets association 0.57 with lung cancer (MONDO_0008903)
- Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254)
- Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.50 with colorectal cancer (MONDO_0005575)
- Small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"RICTOR" OR ABSTRACT:"RICTOR" OR TITLE:"RPTOR independent companion of MTOR complex 2" OR ABSTRACT:"RPTOR independent companion of MTOR complex 2" OR TITLE:"Rapamycin-insensitive companion of mTOR" OR ABSTRACT:"Rapamycin-insensitive companion of mTOR" OR TITLE:"MGC39830" OR ABSTRACT:"MGC39830" OR TITLE:"AVO3" OR ABSTRACT:"AVO3" OR TITLE:"KIAA1999" OR ABSTRACT:"KIAA1999") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RICTOR, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetBARD1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetPER1
Shares Lung cancer (all types), Skin cancer (all types), Gastric & gastro-oesophageal junction cancer, Melanoma.
- TargetACVR1B
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), Melanoma.
- TargetAFDN
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), Melanoma.
- TargetATP2B3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), Melanoma.
- TargetSMAD3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetPTPRC
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), Gastric & gastro-oesophageal junction cancer.